Angeion v. Cardiac Pacemakers, Inc.
This article was originally published in The Gray Sheet
Magistrate judge recommends in a Report and Recommendation that a Minneapolis district court judge grant Angeion's motions for summary judgment and deny the Guidant subsidiary's counter motions for summary judgment of non-infringement that its Mini I and II automatic implantable cardioverter defibrillators infringe certain claims of three Angeion patents related to smaller size, smaller capacitance and "Hot Can-like" features of Angeion devices. The judge also recommends that a claim related to a fourth Angeion patent be dismissed. Angeion and CPI have up to twenty days to file responses to the report, after which time the district court judge will make a final ruling. A jury will consider sometime this fall claims of validity and enforceability of the patents, as well as any possible damages or willful infringement...
You may also be interested in...
France has announced a number of emergency measures to protect drug supplies threatened by the spread of the coronavirus.
Major generics companies have donated hydroxychloroquine sulfate doses for research and treatment of coronavirus. Companies are also donating hand sanitizer and personal protective equipment and are preparing to ramp up manufacturing and production.
Inovio forges ahead into Phase I trials with DNA-based vaccine candidate, but can it prove skeptics wrong?